Dr. Apolo on Avelumab for Metastatic Urothelial Carcinoma

Andrea B. Apolo, MD
Published: Wednesday, May 03, 2017



Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses avelumab (Bavencio) in patients with metastatic urothelial carcinoma from the phase Ib JAVELIN solid tumor trial.

There were 2 cohorts investigated in this study with 44 patients and 200 patients, respectively, explains Apolo. The data from both cohorts were pulled together, which determined that 150 patients with a follow-up of greater then 6 months had an overall response rate of 17.6%.

There were even responses in patients who had poor prognostic features demonstrating how well tolerated avelumab was in this patient population, states Apolo.
 


Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses avelumab (Bavencio) in patients with metastatic urothelial carcinoma from the phase Ib JAVELIN solid tumor trial.

There were 2 cohorts investigated in this study with 44 patients and 200 patients, respectively, explains Apolo. The data from both cohorts were pulled together, which determined that 150 patients with a follow-up of greater then 6 months had an overall response rate of 17.6%.

There were even responses in patients who had poor prognostic features demonstrating how well tolerated avelumab was in this patient population, states Apolo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x